tailieunhanh - Báo cáo y học: "Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases."

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. | Furuse and Hashimoto Annals of General Psychiatry 2010 9 17 http content 9 1 17 ANNALS OF GENERAL PSYCHIATRY CASE REPORT Open Access Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia report of five cases Tsutomu Furuse 1 and Kenji Hashimoto2 Abstract Background Atypical antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects EPS than typical antipsychotic drugs but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Although understanding of the pathophysiology of akathisia remains limited it seems that a complex interaction of several neurotransmitter systems plays a role in its pathophysiology. The endoplasmic reticulum protein sigma-1 receptors have been shown to regulate a number of neurotransmitter systems in the brain. Methods We report on five cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the akathisia of patients with schizophrenia treated with the new atypical antipsychotic drug blonanserin. Results The global score on the Barnes Akathisia Scale in five patients with schizophrenia treated with blonanserin rapidly decreased after fluvoxamine treatment. Conclusion Doctors should consider that fluvoxamine may be an alternative approach in treating akathisia associated with atypical antipsychotic drugs. Background Atypical antipsychotic drugs have been reported to cause a fewer incidences of extrapyramidal side effects EPS than typical antipsychotic drugs but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Akathisia is one of the common and distressing EPS of antipsychotic drugs 1 2 . The development of akathisia can adversely affect patients adherence to medication and as a consequence have a negative impact on long-term treatment outcomes in patients with schizophrenia 3 4 . .